The digital media CIO España has reported on one of the latest European projects in which we have been involved. It is BEAMER, an initiative backed by Europe, whose aim is to find out why patients do not adhere to their treatments and to look for possible solutions to this problem.
According to the World Health Organisation (WHO), 50% of patients do not take the medication prescribed by their doctors. This not only slows down the effects of therapy but also impairs their quality of life and can even be a cause of premature death. Going a step further, this lack of adherence to treatment can lead to relapses in the disease and increase the need for healthcare.
In this sense, the BEAMER project (BEhavioral and Adherence Model for improving quality, health outcomes, and cost-effectiveness of healthcaRe), which started in September 2021, seeks to address this reality through Artificial Intelligence.
With almost €12 million in funding, this initiative coordinated by the University of Porto in Portugal and co-led by Pfizer and Merck KGaA aims to have results by August 2026.
How to improve adherence and effectiveness of medical treatments with Artificial Intelligence?
By analyzing the factors that cause patients not to comply with specified treatments. This is precisely where AI is able to collate behavioral factors within a computational model. It is then possible to offer hypotheses as to why the problem occurs and how to improve efficacy.
As CIO refers, the purpose of the model is to identify the practical aspects that drive non-compliance. This, in turn, will allow the prediction and optimization of treatments based on the population.
